Tumor HLA-II expression is associated with improved prognosis and response to anti-PD1/PD-L1 therapies, as well as an increase in tumor-infiltrating lymphocytes (TILs) and interferon signaling10–14. The gene discussed is CD274; the disease is neoplasm.